Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Sexually Transmitted Diseases Prof.Dr.Fehmi Tabak Cerrahpasa Medical Faculty Department of Infectious Diseases 8 Aralık 2010 Topics • Background Information • “Sores” • “Drips” • Role of STDs in HIV Transmission 2 Background Information 3 Background Epidemiology 4 Syndromes • • • • • Urethritis Genital ulcer adenopathy syndrome Mucopurulent cervicitis Pelvic inflamatuar diseases (PID) Vaginitis Background STDs of Concern • “Sores” (ulcers) – Syphilis – Genital herpes (HSV-2, HSV-1) – Others uncommon in the Turkey • Lymphogranuloma venereum • Chancroid • Granuloma inguinale 6 Background STDs of Concern (continued) • “Drips” (discharges) – – – – – – Gonorrhea Chlamydia Nongonococcal urethritis Mucopurulent cervicitis Trichomonas vaginitis / urethritis Candidiasis (vulvovaginal, less problems in men) • Other major concerns – Genital HPV (especially type 16, 18) and Cervical Cancer 7 “Sores” Syphilis Genital Herpes (HSV-2, HSV-1) 8 Genital Ulcer Diseases – Does It Hurt? Sores • Painful – Chancroid – Genital herpes simplex • Painless – Syphilis – Lymphogranuloma venereum – Granuloma inguinale 9 Primary Syphilis - Clinical Manifestations Sores • Incubation: 10-90 days (average 3 weeks) • Chancre – Early: macule/papule erodes – Late: clean based, painless, indurated ulcer with smooth firm borders – Unnoticed in 15-30% of patients – Resolves in 1-5 weeks – HIGHLY INFECTIOUS 10 Primary Syphilis -Chancre -LAP Sores 11 Secondary Syphilis - Clinical Manifestations Sores • Represents hematogenous dissemination of spirochetes • Usually 2-8 weeks after chancre appears • Findings: – – – – rash - whole body (includes palms/soles) mucous patches condylomata lata - HIGHLY INFECTIOUS constitutional symptoms • Sn/Sx resolve in 2-10 weeks 12 Secondary Syphilis • • • • • • • • Rash Generalized LAP Condylomata lata CNS involvement Fever Glomerulonephritis Hepatitis Artralgia Sores Secondary Syphilis Rash Source: Florida STD/HIV Prevention Training Center 14 Sores Secondary Syphilis: Generalized Body Rash Source: CDC/NCHSTP/Division of STD Prevention, STD Clinical Slides 15 Sores Secondary Syphilis Rash Source: Florida STD/HIV Prevention Training Center 16 Sores Secondary Syphilis Rash Source: Cincinnati STD/HIV Prevention Training Center 17 Sores Secondary Syphilis Source: Diepgen TL, Yihune G et al. Dermatology Online Atlas 18 Secondary Syphilis – Condylomata Lata Source: Florida STD/HIV Prevention Training Center Sores 19 Tersier and late syphilis • Gom (Syphilitic granulomas) • CNS and CVS involvement Syphilis • Latent syphilis Serology (+), Clinic (-) Varies from several months to several years More duration less infectivity Early (<2 years) Late (>2 years) • Neurosyphilis Any neurological symptom or sign Syphilis - Diagnose • Dark field microscopy • Serology Syphilis - Diagnose • Non-spesific serological tests • VDRL • RPR • Spesific serological tests • • • • FTA-ABS TPHA MHA-TP ELISA - The only positive thing of my life is my VDRL test!!! Sores Genital Herpes Simplex - Clinical Manifestations • Direct contact – may be with asymptomatic shedding • Primary infection commonly asymptomatic; symptomatic cases sometimes severe, prolonged, systemic manifestations • Vesicles painful ulcerations crusting • Recurrence a potential • Diagnosis: – – – – Tzanck smear Culture Serology (Western blot) PCR 24 Sores Epidemiology of Genital Herpes • One of the 3 most common STDs, increased 30% from late 70s to early 90s • 25% of US population by age 35 • HSV-2: 80-90%, HSV-1: 10-20% (majority of infections in some regions) • Most cases subclinical • Transmission primarily from subclinical infection • Complications: neonatal transmission, enhanced HIV transmission, psychosocial issues 25 Sores Genital Herpes Simplex 26 Sores Genital Herpes Simplex in Females Source: Centers for Disease Control and Prevention 27 “Drips” Gonorrhea Nongonococcal urethritis Chlamydia Mucopurulent cervicitis Trichomonas vaginitis and urethritis Candidiasis 28 Drips Gonorrhea - Clinical Manifestations • Urethritis - male – – – – Incubation: 1-14 d (usually 2-5 d) Sx: Dysuria and urethral discharge (5% asymptomatic) Dx: Gram stain urethral smear (+) > 98% culture Complications • Urogenital infection - female – – – – Endocervical canal primary site 70-90% also colonize urethra Incubation: unclear; sx usually in l0 d Sx: majority asymptomatic; may have vaginal discharge, dysuria, urination, labial pain/swelling, abd. pain – Dx: Gram stain smear (+) 50-70% culture – Complications 29 Urethritis Gonococcic IP 2-7 days Nongonococcic 10-21 days Initial Acute Subacute Discharge Yellow, profuse Moderate Less, açık renkli Mild Dysuria Urethral discharge Drips Gonorrhea Source: Florida STD/HIV Prevention Training Center 32 Drips Gonorrhea Gram Stain Source: Cincinnati STD/HIV Prevention Training Center 33 Drips Nongonococcal Urethritis Source: Diepgen TL, Yihune G et al. Dermatology Online Atlas 34 Drips Nongonococcal Urethritis • Etiology: – 20-40% C. trachomatis – 20-30% genital mycoplasmas (Ureaplasma urealyticum, Mycoplasma genitalium) – Occasional Trichomonas vaginalis, HSV – Unknown in ~50% cases • Sx: Mild dysuria, mucoid discharge • Dx: Urethral smear 5 PMNs (usually 15)/OI field Urine microscopic 10 PMNs/HPF Leukocyte esterase (+) 35 Drips Chlamydia Life Cycle Source: California STD/HIV Prevention Training Center 36 Drips Chlamydia trachomatis • Responsible for causing: – – – – – Cervicitis, Urethritis Proctitis Lymphogranuloma venereum Pelvic inflammatory disease • Potential to transmit to newborn during delivery – Conjunctivitis, pneumonia 37 Lymphogranuloma venereum LGV GROOVE’ s SIGN Drips Normal Cervix Source: Claire E. Stevens, Seattle STD/HIV Prevention Training Center 39 Drips Chlamydia Cervicitis Source: St. Louis STD/HIV Prevention Training Center 40 Drips Mucopurulent Cervicitis Source: Seattle STD/HIV Prevention Training Center 41 Drips Laboratory Tests for Chlamydia • Tissue culture has been the standard – Specificity approaching 100% – Sensitivity ranges from 60% to 90% • Non-amplified tests – Enzyme Immunoassay (EIA), e.g. Chlamydiazyme • sensitivity and specificity of 85% and 97% respectively • useful for high volume screening • false positives – Nucleic Acid Hybridization (NA Probe), e.g. Gen-Probe Pace-2 • sensitivities ranging from 75% to 100%; specificities greater than 95% • detects chlamydial ribosomal RNA • able to detect gonorrhea and chlamydia from one swab • need for large amounts of sample DNA 42 Drips Laboratory Tests for Chlamydia (continued) • DNA amplification assays – polymerase chain reaction (PCR) – ligase chain reaction (LCR) • Sensitivities with PCR and LCR 95% and 8598% respectively; specificity approaches 100% • LCR ability to detect chlamydia in first void urine 43 Drips Chlamydia Direct Fluorescent Antibody (DFA) Source: Centers for Disease Control and Prevention 44 Drips Pelvic Inflammatory Disease (PID) • l0%-20% women with GC develop PID • In Europe and North America, higher proportion of C. trachomatis than N. gonorrhoeae in women with symptoms of PID • CDC minimal criteria – uterine adnexal tenderness, cervical motion tenderness • Other symptoms include – endocervical discharge, fever, lower abd. pain • Complications: – Infertility: 15%-24% with 1 episode PID secondary to GC or chlamydia – 7X risk of ectopic pregnancy with 1 episode PID – chronic pelvic pain in 18% 45 HPV and Cervical Cancer 46 HPV and Cervical Cancer HPV and Cervical Cancer • Infection is generally indicated by the detection of HPV DNA • HPV infection is causally associated with cervical cancer and probably other anogenital squamous cell cancers (e.g. anal, penile, vulvar, vaginal) • Over 99% of cervical cancers have HPV DNA detected within the tumor • Routine Pap smear screening ensures early detection (and treatment) of pre-cancerous lesions 47 HPV and Cervical Cancer Estimates for HPV-Associated Cancers • Cervical cancer: – In the U.S., an estimated 14,000 cases and 5,000 deaths – Worldwide, an estimated 450,000 cases and 200,000 deaths 48 HPV and Cervical Cancer Perianal Wart Source: Cincinnati STD/HIV Prevention Training Center 49 HPV and Cervical Cancer HPV Penile Warts Source: Cincinnati STD/HIV Prevention Training Center 50 HIV Infection • Infection of immun system • Seen oppurtunistic infections and neoplastic diseases in the last stage Transmission Risks Transmission Sexual activity Risk Anal sex HIV+M M/F 1/3-1/10 Vaginal sex HIV+M F 1/75-1/100 Vaginal sex HIV+F Oral sex - M 1/300-1/1000 ???? HBV Infection HBV • Carrier : 2-3.000.000 • CHB (25%) : 500-750.000 • Cihrosis and HCC(ex)/year : 5000 CHB – Epidemiology 1/3 - %5 HBsAg Prevalance 1/3-%5 8% -HİGH 2-7% - Moderate <2% - Low Genital siğiller • HPV (human papilloma virus) etkendir • Erkek ve kadın genital bölgesinde ve anus çevresinde sert, ağrısız, küçük siğillerdir. • •Virüsün 6 ve 11. alt tipleri dış genital bölgede; • •16, 18 ve 31. alt tipleri ise, servikal displazi ve karsinomla ilişkilidir. Korunma yolları •Şüpheli cinsel temastan kaçının •Tek eşliliğe yönelin •Riskli kişilere HBV aşısı uygulayın •Kondom kullanın •Uyuşturucu ve alkol aldıktan sonra şüpheli cinsel temastan kaçının